Novel (Q)SAR models for prediction of reversible and time-dependent inhibition of cytochrome P450 enzymes

The 2020 FDA drug-drug interaction (DDI) guidance includes a consideration for metabolites with structural alerts for potential mechanism-based inhibition (MBI) and describes how this information may be used to determine whether in vitro studies need to be conducted to evaluate the inhibitory potent...

Disgrifiad llawn

Manylion Llyfryddiaeth

Prif Awduron:	Sadegh Faramarzi, Arianna Bassan, Kevin P. Cross, Xinning Yang, Glenn J. Myatt, Donna A. Volpe, Lidiya Stavitskaya
Fformat:	Artigo
Iaith:	Inglês
Cyhoeddwyd:	Frontiers Media S.A. 2025-02-01
Cyfres:	Frontiers in Pharmacology
Pynciau:	CYP = cytochrome P450 reversible inhibition time dependent inhibition QSAR SAR computational model
Mynediad Ar-lein:	https://www.frontiersin.org/articles/10.3389/fphar.2024.1451164/full
Tagiau:	Ychwanegu Tag Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!